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iscussion
r Frank W. Sellke (Boston, Mass). This is a very nice in vitro
tudy of the effects of overexpression of ILK on cardiac stem cell
rowth.
I have a couple questions. Was the purpose of this study just to
ncrease expansion of the stem cell population, or do you think that
t perhaps could overcome some of the negative influences of
schemia, diabetes, and similar issues on stem cell engraftment and
unction?
Second, do you have any evidence from in vivo studies that this
ill be translated into a physiologic or potentially a clinical ben-fit? s
The Journal of ThoracicFinally, how does this treatment potentially affect the pheno-
ype of the cells or function of the actual cells, other than what you
ave described here?
Dr Coles. Thank you for those insightful questions. The first
wo seem to pertain to the in vivo effect of the cells, and we have
ot had the opportunity to transplant the CSs into a mouse model
f severe combined immunodeficiency, for example, to see what
appens to them in vivo, in terms of their differentiation, or their
esistance to ischemic injury. We would predict that ILK gain-of-
unction, since it is a pro-survival gene, would tend to oppose
schemic damage to the cells.
The focus of this in vitro study was to identify the effect of this
ovel kinase on signaling in human cardiac progenitor cells and to
ry to understand the biology regarding ILK-mediated self-renewal
ersus differentiation. There is a lot more work to be done to try
o nail down the signaling node elements in these progenitor cells
hat determine their phenotypic outcome.
One of the concerns, of course, is that ILK is an oncogene, so
e would probably, in terms of ultimate clinical application, want
o look for small molecule agonists of ILK rather than using the
ene per se.
We do have something in our favor: Cardiac cells are inher-
ntly resistant to oncogenesis, so that we probably have some more
atitude in terms of driving these cells to a pro-survival state.
Taken together, our data, although in vitro, indicate that ILK
epresents a novel and potentially useful target in cardiac progen-
tor cell signaling.
Dr Paul A. Kurlansky (Miami, Fla). Cardiomyocytes are
nder extreme control, not even in an ischemic situation but just in
he regular situation. The regulation of stem cell development is
bviously extremely tightly controlled. Do you have any insight as
o how this promoter might interact with the control mechanisms
hat exist just in the normal adult heart?
Dr Coles. We know that ILK is present in normal cardiac
issue. Obviously, in these experiments, all we can conclude is that
hen you overexpress the gene, it tends to drive the cells into a
elf-renewal mode and/or to promote asynchronous division into
erminally differentiated cardiac cells. Whether or not it is acti-
ated, let’s say, in response to an endogenous myocardial damage
ignal, we do not know that in vivo.
and Cardiovascular Surgery ● Volume 132, Number 6 1279
